RT Journal Article
SR Electronic
T1 Comparative Transcriptome Analysis of Acne vulgaris, Rosacea, and Hidradenitis Suppurativa Supports High Dose Dietary Zinc as a Therapeutic Agent
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.28.23299152
DO 10.1101/2023.11.28.23299152
A1 Li, Li
A1 Hajam, Irshad
A1 McGee, Jean S.
A1 Tang, Zhengkuan
A1 Zhang, Ye
A1 Badey, Nikil
A1 Mintzer, Esther
A1 Zhang, Zhenrui
A1 Liu, George Y.
A1 Church, George M.
A1 Wang, Yu
YR 2023
UL http://medrxiv.org/content/early/2023/12/04/2023.11.28.23299152.abstract
AB Acne vulgaris, rosacea, and hidradenitis suppurativa are enduring inflammatory skin conditions that frequently manifest with akin clinical attributes, posing a considerable challenge for their distinctive diagnosis. While these conditions do exhibit certain resemblances, they also demonstrate distinct underlying pathophysiological mechanisms and treatment modalities. Delving into both the molecular parallels and disparities among these three disorders can yield invaluable insights for refined diagnostics, effective management, and targeted therapeutic interventions. In this report, we present a comparative analysis of transcriptomic data across these three diseases, elucidating differentially expressed genes and enriched pathways specific to each ailment, as well as those shared among them. We also identified high dose dietary zinc as a potential therapeutic agent and validated its efficacy in an acne mouse model.Competing Interest StatementAll G.M.C COI are listed here: http://arep.med.harvard.edu/gmc/tech.html. All other authors report no conflict of interest.Funding StatementThis work was supported by Leo Foundation (LF-OC-20-000420), Strategic Priority Research Program of The Chinese Academy of Sciences (XDB0480000) and National Institute of Health (R01AI141401).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Microarray and RNA-Seq studies published until July 2023, focusing on skin samples associated with Rosacea, Acne, and hidradenitis suppurativa, were sourced by querying the Gene Expression Omnibus (GEO) 21 using the following key words: (Acne OR Rosacea OR hidradenitis suppurativa OR HS) AND (RNA-seq OR Expression profiling OR high throughput sequencing)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll primary gene expression data are available from Gene Expression Omnibus. All analyzed results are available on Zenodo (8343604).